Array BioPharma reports positive survival results for melanoma drugs

Array BioPharma reports positive survival results for melanoma drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) andFrance-based Pierre Fabreannounced results of a study of overall survival in patients with BRAF -mutant melanoma, indicating that treatment with... Read More

Wednesday February 7, 2018 0 comments Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Victor Sandor

Array’s triplet drug combination found effective for colorectal cancer treatment

Array’s triplet drug combination found effective for colorectal cancer treatment

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet... Read More

Monday January 22, 2018 0 comments Tags: Boulder, Array BioPharma, binimetinib, encorafenib, cetuximab, Pierre Fabre

Array BioPharma to collaborate with Pfizer on clinical drug trials

Array BioPharma to collaborate with Pfizer on clinical drug trials

BOULDER -- Array BioPharma (Nasdaq: ARRY) today announced it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel... Read More

Tuesday December 19, 2017 0 comments Tags: Boulder, Array BioPharma, Pfizer, Ron Squarer

CBSA to honor life science innovators, leaders tonight

CBSA to honor life science innovators, leaders tonight

DENVER -- Colorado BioScience Association (CBSA) will highlight a banner year marked by acquisitions, investments, discoveries and partnerships during its 14 th Annual Awards Dinner tonight in... Read More

Thursday November 9, 2017 0 comments Tags: Denver, CBSA, April Giles, Array BioPharma, miRagen Therapeutics, Sharklet Technologies, Cerescan, Eximis Surgical, Ocugen, Boettcher Foundation

Array BioPharma to raise $225M through stock sale

Array BioPharma to raise $225M through stock sale

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced the pricing of an underwritten public offering of 20,930,232 shares of its common stock at a public offering price of$10.75per share. ... Read More

Friday September 15, 2017 0 comments Tags: Boulder, Array BioPharma

Array BioPharma announces FDA acceptance to review new melanoma drug applications

Array BioPharma announces FDA acceptance to review new melanoma drug applications

BOULDER -- Array BioPharma (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Applications (NDAs) to support use of the combination of... Read More

Wednesday September 13, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, encorafenib, binimetinib

Array BioPharma and Amgen collaborate to develop autoimmune drugs

Array BioPharma and Amgen collaborate to develop autoimmune drugs

BOULDER/THOUSAND OAKS, Calif. -- California-based Amgen (NASDAQ:AMGN) and Boulder-based Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development... Read More

Wednesday July 19, 2017 0 comments Tags: Boulder, Array BioPharma, Amgen, Nicholas Saccomano, Flavius Martin

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

BOULDER -- Array BioPharma (Nasdaq:ARRY) today announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) to support use of the combination of... Read More

Wednesday July 5, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, binimetinib, encorafenib